TITLE

Maraviroc

AUTHOR(S)
Cada, Dennis J.; Levien, Terri; Baker, Danial E.
PUB. DATE
November 2007
SOURCE
Hospital Pharmacy;Nov2007, Vol. 42 Issue 11, p1046
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on maraviroc. It is an orally-available selective chemokine receptor CCR5 antagonist with potent anti-HIV-1 activity. An increase in liver-related adverse reactions was observed with the drug compared with placebo. A small increase in maraviroc peak concentration was observed when administered in conjunction with nevirapine.
ACCESSION #
27587065

 

Related Articles

  • Increased ALT levels with paracetamol 4 g/day.  // Reactions Weekly;7/15/2006, Issue 1110, p3 

    This article presents the results of a U.S. randomized, longitudinal study on the adverse association of paracetamol therapy with the risk of hepatotoxicity. According to the researchers significant increase in maximum ALT values occurred in paracetamol use as compared with placebo use and...

  • Tipranavir/ritonavir.  // Reactions Weekly;8/19/2006, Issue 1115, p21 

    The article discusses research being done on severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir. It references a study by B. J¨lg, J.R. Bogner and F.D. Goebel published in the July 2006 issue of "AIDS." The clinical history of the patient and the...

  • Therapeutic targets for HIV-1 infection in the host proteome. Liang, Winnie S.; Maddukuri, Anil; Teslovich, Tanya M.; de la Fuente, Cynthia; Agbottah, Emmanuel; Dadgar, Shabnam; Kehn, Kylene; Hautaniemi, Sampsa; Pumfery, Anne; Stephan, Dietrich A.; Kashanchi, Fatah // Retrovirology;2005, Vol. 2, p20 

    Background: Despite the success of HAART, patients often stop treatment due to the inception of side effects. Furthermore, viral resistance often develops, making one or more of the drugs ineffective. Identification of novel targets for therapy that may not develop resistance is sorely needed....

  • SAVVY (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana. Peterson, Leigh; Nanda, Kavita; Opoku, Baafuor Kofi; Ampofo, William Kwabena; Owusu-Amoako, Margaret; Boakye, Andrew Yiadom; Rountree, Wes; Troxler, Amanda; Dominik, Rosalie; Roddy, Ronald; Dorflinger, Laneta // PLoS Clinical Trials;Dec2007, Vol. 4 Issue 12, p1 

    Objective. The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk. Methodology/Principal Findings. This was a Phase 3, double-blind, randomized, placebo-controlled trial....

  • Nevirapine and hepatotoxicity.  // WHO Drug Information;2004, Vol. 18 Issue 1, p31 

    Reports on the addition of safety information in the label of the antiretroviral agent nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infections, to clarify risk factors for hepatotoxicity. Patients at high risk of hepatotoxicity; Monitoring of patients...

  • Didanosine.  // Reactions Weekly;11/18/2006, Issue 1128, p9 

    The article presents case reports of patients who developed hepatoportal sclerosis during antiretroviral treatment with didanosine for HIV infection. Liver disease developed in three of the patients and esophageal varices and variceal bleeding were present in one patient each. Portal vein...

  • LIVER PROBLEMS WITH RITONAVIR.  // AIDS Patient Care & STDs;Mar2000, Vol. 14 Issue 3, p169 

    Reports that HIV patients who take ritonavir are at an increased risk for developing liver problems. Percentage of patients who develop liver problems from ritonavir use; Occurrence of coinfection cases of hepatitis C among patients.

  • Raltegravir Treatment for Antiretroviral-resistant HIV Infection. Winslow, Dean L. // Infectious Disease Alert;Mar2009, Vol. 28 Issue 6, p29 

    The merck integrase inhibitor, raltegravir, was studied in two identical trials in different geographic locations to evaluate its safety and efficacy vs placebo in combination with optimized background therapy in patients infected with 3-drug class-resistant (3DCR) HIV-1. Patients were...

  • Pre-existing Conditions, Placebo Reactions, and "Side Effects". Green, D.M. // Annals of Internal Medicine;Feb64 Part 2, Vol. 60 Issue 2, p255 

    Explores the possible relationship between pre-treatment conditions and placebo reactions and the subsequent appearance of symptoms that could be regarded as drug side effects. Adverse effects that may follow the giving of a presumed medication; Range of frequency in the reported symptoms;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics